Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Inclusion Criteria: * De novo untreated ALL patients diagnosed by the bone marrow morphology, immunophenotype. * 65 ≥ Age (years) ≥ 18 , male or female, * ECOG Performance status of 0, 1, or 2. * Patients must fulfill the following laboratory values 1. Total bilirubin ≤2 ULN (corrected for same age) 2. AST and ALT ≤3 ULN ( corrected for same ages) 3. Serum creatinine ≤2 ULN (corrected for same age) * Didn't receive any of the following treatments within 4 weeks before inclusion: chemotherapy, radiotherapy, replacement therapy, operation, long term of glucocorticoid therapy（\>5 days）. * No neurological disorders, no nerve or muscle injury (motor and sensory nerve). * Patient must sign the informed consent and obey the protocol. Exclusion Criteria: * Atopy or allergic to multiple medicines or excipients. * With serious complications that affect compliance. * Serious organ dysfunctions or central nervous system disorders. * Mixed phenotype acute leukemia, (T-B). * Burkitt lymphoma/leukemia. * Suspected or confirmed central nervous system leukemia. * Diabetes. * Received antifungal treatment with triazole agents within 1 month before inclusion. * Reliance of antipyretic and analgesic medicines or psychotropic medicines. * Undergoing or has undergone other clinical trials in 4 weeks before inclusion. * Pregnant women, women of breast feeding or childbearing potential without contraception. * Psychological disorders that affect signing consent. * The investigators believe that patients who are not suitable for inclusion.